Preclinical and early‐stage clinical trials have demonstrated the safety profile and preliminary activity of monotherapy with pan‐PI3K inhibitors in some tumor types, especially for breast cancer.351, 352, 353. Here, PIK3CA is linked to breast carcinoma.